Literature DB >> 10981094

Optimal blood pressure on antihypertensive medication.

J M Flack1.   

Abstract

The optimal blood pressure (BP) level for a patient on antihypertensive medication should maximize the patient's well-being and simultaneously lower the risk for pressure-related cardiovascular-renal complications. The clinical expression of pressure-related complications such as stroke, heart failure, renal insufficiency, peripheral arterial disease, and cognitive decline takes many years to decades to manifest. Accordingly, the attainment of the ultimate target BP is rarely necessary, or even desirable, over short time periods (eg, weeks) because the absolute clinical risk within these time periods is quite low. However, overmedication or aggressive BP lowering over the short term increases the likelihood of treatment-related side effects. Thus, attainment of goal BP should be accomplished gradually over many weeks to months in order to maximize BP lowering at a given dose of medication(s). Recent target BP goals promulgated by the Sixth Report from the Joint National Committee (JNC VI) are based on the premise that the intensity of treatment directly corresponds to the magnitude of pretreatment risk. Thus, hypertensive persons with diabetes, renal disease, or heart failure have goal BP levels lower than 130/85 mm Hg. All other hypertensive individuals should attain BP levels minimally to lower than 140/90 mm Hg. Finally, there is now appropriate recognition of the pivotal role of BP reduction in forestalling pressure-related cardiovascular complications, even among high-risk persons with diabetes mellitus and renal insufficiency.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10981094     DOI: 10.1007/s11906-999-0052-3

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  31 in total

1.  Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group.

Authors:  I Giatras; J Lau; A S Levey
Journal:  Ann Intern Med       Date:  1997-09-01       Impact factor: 25.391

2.  Inadequate management of blood pressure in a hypertensive population.

Authors:  D R Berlowitz; A S Ash; E C Hickey; R H Friedman; M Glickman; B Kader; M A Moskowitz
Journal:  N Engl J Med       Date:  1998-12-31       Impact factor: 91.245

3.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators.

Authors:  J A Staessen; R Fagard; L Thijs; H Celis; G G Arabidze; W H Birkenhäger; C J Bulpitt; P W de Leeuw; C T Dollery; A E Fletcher; F Forette; G Leonetti; C Nachev; E T O'Brien; J Rosenfeld; J L Rodicio; J Tuomilehto; A Zanchetti
Journal:  Lancet       Date:  1997-09-13       Impact factor: 79.321

4.  Mortality after 10 1/2 years for hypertensive participants in the Multiple Risk Factor Intervention Trial.

Authors: 
Journal:  Circulation       Date:  1990-11       Impact factor: 29.690

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Compliance to treatment for hypertension in elderly patients: the SHEP pilot study. Systolic Hypertension in the Elderly Program.

Authors:  D M Black; R J Brand; M Greenlick; G Hughes; J Smith
Journal:  J Gerontol       Date:  1987-09

7.  Antecedent hypertension confers increased risk for adverse outcomes after initial myocardial infarction.

Authors:  A W Haider; L Chen; M G Larson; J C Evans; M H Chen; D Levy
Journal:  Hypertension       Date:  1997-11       Impact factor: 10.190

8.  Early aggressive antihypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy.

Authors:  H H Parving; A R Andersen; U M Smidt; P A Svendsen
Journal:  Lancet       Date:  1983-05-28       Impact factor: 79.321

9.  Does antihypertensive treatment of the elderly prevent cardiovascular events or prolong life? A meta-analysis of hypertension treatment trials.

Authors:  K A Pearce; C D Furberg; J Rushing
Journal:  Arch Fam Med       Date:  1995-11

10.  Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension.

Authors:  K Sutton-Tyrrell; H G Alcorn; H Herzog; S F Kelsey; L H Kuller
Journal:  Stroke       Date:  1995-08       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.